DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 18-780/S-066

Eli Lilly and Company
Attention: Jeffrey L. Winn, D.D.S., R.Ph.
Senior Regulatory Research Scientist
U.S. Regulatory Affairs
Lilly Corporate Center
Indianapolis, IN 46285

Dear Dr. Winn:

Please refer to your supplemental new drug application dated November 7, 2000, received November 8, 2000, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Humulin R (human insulin [rDNA origin] injection) U-500.

This "Changes Being Effected" supplemental new drug application provides for the following labeling changes:

1. Combination of physician insert and INFORMATION FOR THE PATIENT on a single sheet of paper with instructions to pharmacists to detach INFORMATION FOR THE PATIENT and give to the patient,

2. Additional language for the "good control message" in the DIABETES section of INFORMATION FOR THE PATIENT, and

3. Deletion of the pictorial graphic of carton and vial in the **Identification** section of INFORMATION FOR THE PATIENT.

We completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on November 7, 2000. However, when you print final printed label next time or within six-month, whichever comes first, move WARNINGS section in physician insert to after CONTRAINDICATIONS but before PRECAUTIONS in accordance with 21CFR 201.57 and notify the Agency of the revision in an annual report.

In addition, submit three copies of the introductory promotional materials that you propose to use for this product. Submit all proposed materials in draft or mock-up form, not final print. Send one copy to this division and two copies of both the promotional materials and the package inserts directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-42
Food and Drug Administration
5600 Fishers Lane
Rockville, MD 20857

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, call Julie Rhee, Regulatory Project Manager, at (301) 827-6424.

Sincerely,

{See appended electronic signature page}

David G. Orloff, M.D.
Director
Division of Metabolic
and Endocrine Drug Products, HFD-510
Office of Drug Evaluation II
Center for Drug Evaluation and Research

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

David Orloff

4/14/03 06:35:44 PM